Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 565-580

  Avtanski, Dimiter B ^a   Nagalingam, Arumugam ^a   Bonner, Michael Y ^b   Arbiser, Jack L ^b,c   Saxena, Neeraj K ^d   Sharma, Dipali ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; E cadherin; EMT; Honokiol; Stat3; Zeb1

Indexed keywords

HONOKIOL; STAT3 PROTEIN; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; CADHERIN; HOMEODOMAIN PROTEIN; LIGNAN; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL IMMORTALIZATION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG PROTEIN BINDING; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; TUMOR INVASION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BREAST; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; FEMALE; ISOLATION AND PURIFICATION; MAGNOLIA; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MAGNOLIA GRANDIFLORA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIPHENYL COMPOUNDS; BREAST; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; LIGNANS; MAGNOLIA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS;

EID: 84899486834     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.01.004     Document Type: Article

References (79)

1. Ahn K.S., Sethi G., Shishodia S., Sung B., Arbiser J.L., Aggarwal B.B. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol. Cancer Res. MCR 2006, 4:621-633.
2. Arora S., Bhardwaj A., Srivastava S.K., Singh S., McClellan S., Wang B., Singh A.P. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS One 2011, 6:e21573.
3. Arora S., Singh S., Piazza G.A., Contreras C.M., Panyam J., Singh A.P. Honokiol: a novel natural agent for cancer prevention and therapy. Curr. Mol. Med. 2012, 12:1244-1252.
4. Bai X., Cerimele F., Ushio-Fukai M., Waqas M., Campbell P.M., Govindarajan B., Der C.J., Battle T., Frank D.A., Ye K., Murad E., Dubiel W., Soff G., Arbiser J.L. Honokiol, a small molecular weight natural product, inhibits angiogenesis invitro and tumor growth invivo. J.Biol. Chem. 2003, 278:35501-35507.
5. Bar-Sela G., Epelbaum R., Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr. Med. Chem. 2010, 17:190-197.
6. Bates R.C., Mercurio A.M. Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol. Biol. Cell 2003, 14:1790-1800.
7. Battle T.E., Arbiser J., Frank D.A. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 2005, 106:690-697.
8. Belguise K., Guo S., Yang S., Rogers A.E., Seldin D.C., Sherr D.H., Sonenshein G.E. Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res. 2007, 67:11742-11750.
9. Berclaz G., Altermatt H.J., Rohrbach V., Siragusa A., Dreher E., Smith P.D. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int. J. Oncol. 2001, 19:1155-1160.
10. Blick T., Hugo H., Widodo E., Waltham M., Pinto C., Mani S.A., Weinberg R.A., Neve R.M., Lenburg M.E., Thompson E.W. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J.Mammary Gland Biol. Neoplasia 2010, 15:235-252.
11. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
12. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
13. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2002, 8:945-954.
14. Burdelya L., Catlett-Falcone R., Levitzki A., Cheng F., Mora L.B., Sotomayor E., Coppola D., Sun J., Sebti S., Dalton W.S., Jove R., Yu H. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol. Cancer Ther. 2002, 1:893-899.
15. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
16. Choi D.Y., Lee Y.J., Hong J.T., Lee H.J. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease. Brain Res. Bull. 2012, 87:144-153.
17. Chu Q., Ling M.T., Feng H., Cheung H.W., Tsao S.W., Wang X., Wong Y.C. A novel anticancer effect of garlic derivatives: inhibition of cancer cell invasion through restoration of E-cadherin expression. Carcinogenesis 2006, 27:2180-2189.
18. Chua H.L., Bhat-Nakshatri P., Clare S.E., Morimiya A., Badve S., Nakshatri H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007, 26:711-724.
19. Colomiere M., Findlay J., Ackland L., Ahmed N. Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin. Int. J. Biochem. Cell Biol. 2009, 41:1034-1045.
20. Creighton C.J., Chang J.C., Rosen J.M. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J.Mammary Gland Biol. Neoplasia 2010, 15:253-260.
21. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., Rimm D.L., Wong H., Rodriguez A., Herschkowitz J.I., Fan C., Zhang X., He X., Pavlick A., Gutierrez M.C., Renshaw L., Larionov A.A., Faratian D., Hilsenbeck S.G., Perou C.M., Lewis M.T., Rosen J.M., Chang J.C. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13820-13825.
22. Dave B., Mittal V., Tan N.M., Chang J.C. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012, 14:202.
23. Fried L.E., Arbiser J.L. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid. Redox Signal. 2009, 11:1139-1148.
24. Fujita M., Itokawa H., Sashida Y. Yakugaku Zasshi 1973, 93:429-434.
25. Grandis J.R., Drenning S.D., Chakraborty A., Zhou M.Y., Zeng Q., Pitt A.S., Tweardy D.J. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth invitro. J.Clin. Invest 1998, 102:1385-1392.
26. Green S.K., Francia G., Isidoro C., Kerbel R.S. Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy invitro. Mol. Cancer Ther. 2004, 3:149-159.
27. Haura E.B., Turkson J., Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2005, 2:315-324.
28. Hibasami H., Achiwa Y., Katsuzaki H., Imai K., Yoshioka K., Nakanishi K., Ishii Y., Hasegawa M., Komiya T. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. Int. J. Mol. Med. 1998, 2:671-673.
29. Hirano T., Gotoh M., Oka K. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci. 1994, 55:1061-1069.
30. Huber M.A., Azoitei N., Baumann B., Grunert S., Sommer A., Pehamberger H., Kraut N., Beug H., Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J.Clin. Invest. 2004, 114:569-581.
31. Idowu M.O., Kmieciak M., Dumur C., Burton R.S., Grimes M.M., Powers C.N., Manjili M.H. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum. Pathol. 2012, 43:364-373.
32. Ishitsuka K., Hideshima T., Hamasaki M., Raje N., Kumar S., Hideshima H., Shiraishi N., Yasui H., Roccaro A.M., Richardson P., Podar K., Le Gouill S., Chauhan D., Tamura K., Arbiser J., Anderson K.C. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 2005, 106:1794-1800.
33. Kim S.H., Nagalingam A., Saxena N.K., Singh S.V., Sharma D. Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis 2011, 32:359-367.
34. Lee J., Jung E., Park J., Jung K., Lee S., Hong S., Park E., Kim J., Park S., Park D. Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Med. 2005, 71:338-343.
35. Lin Y.R., Chen H.H., Ko C.H., Chan M.H. Differential inhibitory effects of honokiol and magnolol on excitatory amino acid-evoked cation signals and NMDA-induced seizures. Neuropharmacology 2005, 49:542-550.
36. Lo Y.C., Teng C.M., Chen C.F., Chen C.C., Hong C.Y. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem. Pharmacol. 1994, 47:549-553.
37. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
38. Marotta L.L., Almendro V., Marusyk A., Shipitsin M., Schemme J., Walker S.R., Bloushtain-Qimron N., Kim J.J., Choudhury S.A., Maruyama R., Wu Z., Gonen M., Mulvey L.A., Bessarabova M.O., Huh S.J., Silver S.J., Kim S.Y., Park S.Y., Lee H.E., Anderson K.S., Richardson A.L., Nikolskaya T., Nikolsky Y., Liu X.S., Root D.E., Hahn W.C., Frank D.A., Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J.Clin. Invest. 2011, 121:2723-2735.
39. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leeder J.S., Freedman M., Cohen A., Gazit A., Levitzki A., Roifman C.M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379:645-648.
40. Morel A.P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888.
41. Nagalingam A., Arbiser J.L., Bonner M.Y., Saxena N.K., Sharma D. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res. 2012, 14:R35.
42. Nagase H., Ikeda K., Sakai Y. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness invitro. Planta Med. 2001, 67:705-708.
43. Oh J.H., Kang L.L., Ban J.O., Kim Y.H., Kim K.H., Han S.B., Hong J.T. Anti-inflammatory effect of 4-O-methylhonokiol, compound isolated from Magnolia officinalis through inhibition of NF-kappaB [corrected]. Chem.-Biol. Interact. 2009, 180:506-514.
44. Prasad C.P., Rath G., Mathur S., Bhatnagar D., Parshad R., Ralhan R. Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer 2009, 9:325.
45. Radisky D.C., LaBarge M.A. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2008, 2:511-512.
46. Sanchez-Tillo E., Siles L., de Barrios O., Cuatrecasas M., Vaquero E.C., Castells A., Postigo A. Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am. J. Cancer Res. 2011, 1:897-912.
47. Santisteban M., Reiman J.M., Asiedu M.K., Behrens M.D., Nassar A., Kalli K.R., Haluska P., Ingle J.N., Hartmann L.C., Manjili M.H., Radisky D.C., Ferrone S., Knutson K.L. Immune-induced epithelial to mesenchymal transition invivo generates breast cancer stem cells. Cancer Res. 2009, 69:2887-2895.
48. Saxena N.K., Fu P.P., Nagalingam A., Wang J., Handy J., Cohen C., Tighiouart M., Sharma D., Anania F.A. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010, 139:1762-1773. 1773, 1761-1765.
49. Saxena N.K., Sharma D., Ding X., Lin S., Marra F., Merlin D., Anania F.A. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67:2497-2507.
50. Saxena N.K., Vertino P.M., Anania F.A., Sharma D. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J.Biol. Chem. 2007, 282:13316-13325.
51. Schmalhofer O., Brabletz S., Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009, 28:151-166.
52. Sehrawat A., Singh S.V. Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells. Cancer Prev. Res. (Phila) 2011, 4:1107-1117.
53. Sharma D., Saxena N.K., Davidson N.E., Vertino P.M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 2006, 66:6370-6378.
54. Sharma D., Wang J., Fu P.P., Sharma S., Nagalingam A., Mells J., Handy J., Page A.J., Cohen C., Anania F.A., Saxena N.K. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 2010, 52:1713-1722.
55. Sheu M.L., Chiang C.K., Tsai K.S., Ho F.M., Weng T.I., Wu H.Y., Liu S.H. Inhibition of NADPH oxidase-related oxidative stress-triggered signaling by honokiol suppresses high glucose-induced human endothelial cell apoptosis. Free Radic. Biol. Med. 2008, 44:2043-2050.
56. Shigemura K., Arbiser J.L., Sun S.Y., Zayzafoon M., Johnstone P.A., Fujisawa M., Gotoh A., Weksler B., Zhau H.E., Chung L.W. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 2007, 109:1279-1289.
57. Shimono Y., Zabala M., Cho R.W., Lobo N., Dalerba P., Qian D., Diehn M., Liu H., Panula S.P., Chiao E., Dirbas F.M., Somlo G., Pera R.A., Lao K., Clarke M.F. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603.
58. Singh T., Katiyar S.K. Honokiol inhibits non-small cell lung cancer cell migration by targeting PGE(2)-mediated activation of beta-catenin signaling. PLoS One 2013, 8:e60749.
59. Singh T., Prasad R., Katiyar S.K. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death invitro and invivo. Epigenetics 2013, 8:54-65.
60. Sinibaldi D., Wharton W., Turkson J., Bowman T., Pledger W.J., Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 2000, 19:5419-5427.
61. Song H., Wang R., Wang S., Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:4700-4705.
62. Taliaferro-Smith L., Nagalingam A., Zhong D., Zhou W., Saxena N.K., Sharma D. LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 2009, 28:2621-2633.
63. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
64. Tomaskovic-Crook E., Thompson E.W., Thiery J.P. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 2009, 11:213.
65. Tse A.K., Wan C.K., Shen X.L., Yang M., Fong W.F. Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation. Biochem. Pharmacol. 2005, 70:1443-1457.
66. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets 2004, 8:409-422.
67. Turkson J., Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000, 19:6613-6626.
68. Wang T., Chen F., Chen Z., Wu Y.F., Xu X.L., Zheng S., Hu X. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J. Gastroenterol. WJG 2004, 10:2205-2208.
69. Wang X., Duan X., Yang G., Zhang X., Deng L., Zheng H., Deng C., Wen J., Wang N., Peng C., Zhao X., Wei Y., Chen L. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One 2011, 6:e18490.
70. Willis B.C., Liebler J.M., Luby-Phelps K., Nicholson A.G., Crandall E.D., du Bois R.M., Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 2005, 166:1321-1332.
71. Xi S., Gooding W.E., Grandis J.R. Invivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005, 24:970-979.
72. Xiong H., Hong J., Du W., Lin Y.W., Ren L.L., Wang Y.C., Su W.Y., Wang J.L., Cui Y., Wang Z.H., Fang J.Y. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J.Biol. Chem. 2012, 287:5819-5832.
73. Xu Q., Yi L.T., Pan Y., Wang X., Li Y.C., Li J.M., Wang C.P., Kong L.D. Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:715-725.
74. Yang S.E., Hsieh M.T., Tsai T.H., Hsu S.L. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem. Pharmacol. 2002, 63:1641-1651.
75. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
76. Yue P., Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin. Investig. Drugs 2009, 18:45-56.
77. Zhang L.L., Li L., Wu D.P., Fan J.H., Li X., Wu K.J., Wang X.Y., He D.L. A novel anti-cancer effect of genistein: reversal of epithelial mesenchymal transition in prostate cancer cells. Acta Pharmacol. Sin 2008, 29:1060-1068.
78. Zhuo W., Wang Y., Zhuo X., Zhang Y., Ao X., Chen Z. Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway. Lung Cancer 2008, 62:8-14.
79. Zhuo W.L., Wang Y., Zhuo X.L., Zhang Y.S., Chen Z.T. Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem. Biophys. Res. Commun. 2008, 369:1098-1102.